Holen Sie sich die Stockscreener-App
1.19
6.25%
0.07
Schlusskurs vom Vortag:
$1.12
Offen:
$1.12
24-Stunden-Volumen:
7.28M
Relative Volume:
1.99
Marktkapitalisierung:
$264.04M
Einnahmen:
$95,000
Nettoeinkommen (Verlust:
$-327.27M
KGV:
-0.5613
EPS:
-2.12
Netto-Cashflow:
$-239.25M
1W Leistung:
+8.18%
1M Leistung:
-16.20%
6M Leistung:
-45.16%
1J Leistung:
-54.05%
1-Tages-Spanne:
$1.11
$1.23
1-Wochen-Bereich:
$1.03
$1.23
52-Wochen-Spanne:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALLO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.19 | 241.85M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-28 | Bestätigt | B. Riley Securities | Buy |
| 2021-10-20 | Eingeleitet | Cowen | Outperform |
| 2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-10-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Fortgesetzt | Jefferies | Buy |
| 2021-05-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-26 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-11-24 | Eingeleitet | BofA Securities | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
| 2020-04-13 | Eingeleitet | SunTrust | Buy |
| 2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-24 | Eingeleitet | Berenberg | Hold |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-23 | Eingeleitet | Stifel | Hold |
| 2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Allogene Q2 Cash Tops $300 Million - AOL.com
Allogene Therapeutics Inc. Facing Inflection Point in Trend AnalysisPrice Action & Daily Entry Point Alerts - beatles.ru
Real time pattern detection on Allogene Therapeutics Inc. stockJuly 2025 Short Interest & Low Risk Growth Stock Ideas - Newser
Ranking Allogene Therapeutics Inc. among high performing stocks via toolsTrade Volume Summary & Weekly Top Gainers Alerts - Newser
Will Allogene Therapeutics Inc. outperform the marketJuly 2025 Spike Watch & Reliable Price Action Trade Plans - Newser
Full technical analysis of Allogene Therapeutics Inc. stockWeekly Gains Summary & Safe Capital Allocation Plans - Newser
How to track smart money flows in Allogene Therapeutics Inc.Portfolio Profit Report & Community Supported Trade Ideas - Newser
What machine learning models say about Allogene Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Pick Reports - Newser
Backtesting results for Allogene Therapeutics Inc. trading strategiesBreakout Watch & Advanced Swing Trade Entry Plans - Newser
What recovery options are there for Allogene Therapeutics Inc.Weekly Market Summary & Safe Capital Allocation Plans - Newser
Published on: 2025-08-19 03:10:25 - Newser
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - MSN
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call Transcript - MSN
Can swing trading help recover from Allogene Therapeutics Inc. losses2025 Macro Impact & Low Risk Entry Point Tips - Newser
Signal strength of Allogene Therapeutics Inc. stock in tech scannersJuly 2025 Chart Watch & Safe Entry Point Identification - Newser
Will Allogene Therapeutics Inc. benefit from macro trendsJuly 2025 Levels & Weekly High Momentum Picks - Newser
Allogene Therapeutics Inc. stock chart pattern explainedBuy Signal & Breakout Confirmation Trade Signals - Newser
Understanding Allogene Therapeutics Inc.’s price movementTrade Analysis Report & Verified Swing Trading Watchlist - Newser
Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges - TipRanks
Allogene Therapeutics Q2 2025 Earnings Preview: Revenue Expectations Flat, Earnings Estimates Rise - AInvest
Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO) - Seeking Alpha
Crispr Therapeutics shares rise 3.12% intraday after Allogene Therapeutics' positive trial updates. - AInvest
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - 富途牛牛
Allogene's Q2 Loss Narrower Than Expected, Pipeline In Focus - Barchart.com
Allogene Therapeutics shares rise 1.92% premarket after reporting better-than-expected Q2 earnings. - AInvest
Allogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advances - MSN
Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline - Investing.com
Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline By Investing.com - Investing.com South Africa
Allogene Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Oppenheimer Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Allogene Therapeutics Advances in CAR T Cell Therapy - TipRanks
ALPHA3 Trial Update: Contradictions in Enrollment, Data Expectations, and Lymphodepletion Strategies - AInvest
Allogene Therapeutics Q2 2025 Earnings: A Strategic Leap in Cell Therapy Commercialization - AInvest
Transcript : Allogene Therapeutics, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Allogene's Strategic Milestone Progress in 2026 and Its Implications for CAR T Leadership - AInvest
Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts - Investing.com Nigeria
Allogene Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allogene Narrows Loss in Fiscal Q2 - Nasdaq
Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics Advances Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma and Initiates Phase 1 Trials for Autoimmune Disease and Renal Cell Carcinoma - Quiver Quantitative
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Allogene's CAR T Trials Show Promise in Cancer and Autoimmune Disease, $302M Cash Position - Stock Titan
Allogene Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Allogene Therapeutics Inc expected to post a loss of 27 cents a shareEarnings Preview - TradingView
Allogene Therapeutics Inc. stock trend forecastMarket Stability and Long-Term Growth Outlook - Newser
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):